JP2002504328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002504328A5 JP2002504328A5 JP2000532517A JP2000532517A JP2002504328A5 JP 2002504328 A5 JP2002504328 A5 JP 2002504328A5 JP 2000532517 A JP2000532517 A JP 2000532517A JP 2000532517 A JP2000532517 A JP 2000532517A JP 2002504328 A5 JP2002504328 A5 JP 2002504328A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- biotin
- cells
- avidin
- cdna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 20
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 11
- 229960002685 biotin Drugs 0.000 description 10
- 239000011616 biotin Substances 0.000 description 10
- 235000020958 biotin Nutrition 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 8
- 108090001008 Avidin Proteins 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 206010018338 Glioma Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- XWJBVGZSIAZDKJ-FXQIFTODSA-N 2-[3-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]propyl]propanedioic acid Chemical class N1C(=O)N[C@@H]2[C@H](CCCC(C(=O)O)C(O)=O)SC[C@@H]21 XWJBVGZSIAZDKJ-FXQIFTODSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 208000029824 high grade glioma Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 201000011614 malignant glioma Diseases 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108010053763 Pyruvate Carboxylase Proteins 0.000 description 1
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 description 1
- 101150090155 R gene Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 102000035013 scavenger receptor class A Human genes 0.000 description 1
- 108091005451 scavenger receptor class A Proteins 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 108700026215 vpr Genes Proteins 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9803757.5 | 1998-02-23 | ||
| GBGB9803757.5A GB9803757D0 (en) | 1998-02-23 | 1998-02-23 | Fusion proteins |
| GB9813653.4 | 1998-06-24 | ||
| GBGB9813653.4A GB9813653D0 (en) | 1998-06-24 | 1998-06-24 | Fusion proteins |
| PCT/GB1999/000546 WO1999042577A2 (en) | 1998-02-23 | 1999-02-23 | Biotin-binding receptor molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002504328A JP2002504328A (ja) | 2002-02-12 |
| JP2002504328A5 true JP2002504328A5 (https=) | 2006-02-02 |
Family
ID=26313170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000532517A Pending JP2002504328A (ja) | 1998-02-23 | 1999-02-23 | ビオチン結合性レセプター分子 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7208291B2 (https=) |
| EP (1) | EP1056850B1 (https=) |
| JP (1) | JP2002504328A (https=) |
| KR (1) | KR100722578B1 (https=) |
| CN (1) | CN1195852C (https=) |
| AT (1) | ATE274058T1 (https=) |
| AU (1) | AU750444B2 (https=) |
| CA (1) | CA2319039A1 (https=) |
| DE (1) | DE69919515T2 (https=) |
| DK (1) | DK1056850T3 (https=) |
| ES (1) | ES2226340T3 (https=) |
| HU (1) | HUP0101614A3 (https=) |
| NO (1) | NO328139B1 (https=) |
| PL (1) | PL195990B1 (https=) |
| PT (1) | PT1056850E (https=) |
| WO (1) | WO1999042577A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040209294A1 (en) * | 2002-09-02 | 2004-10-21 | National Food Research Institute | Method to produce a receptor chip using biotinylated protein |
| US9623117B2 (en) * | 2011-04-04 | 2017-04-18 | Wisconsin Alumni Research Foundation | Method for selective targeting and entry of bacterial toxins to cells |
| CN113354744A (zh) * | 2013-12-20 | 2021-09-07 | 弗雷德哈钦森癌症研究中心 | 带标签的嵌合效应分子及其受体 |
| EP3288570A4 (en) | 2015-04-29 | 2018-11-21 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4839293A (en) * | 1986-02-24 | 1989-06-13 | The Trustees Of Columbia University In The City Of New York | DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof |
| US5135736A (en) * | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| CA1340977C (en) | 1988-11-15 | 2000-04-25 | Monty Krieger | Scavenger receptor protein and antibody thereto |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5846537A (en) | 1995-06-07 | 1998-12-08 | University Of Rochester | Modified avidin and streptavidin and methods of use thereof |
| US6497881B1 (en) * | 1995-11-30 | 2002-12-24 | New York University | High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein |
-
1999
- 1999-02-23 KR KR1020007009270A patent/KR100722578B1/ko not_active Expired - Fee Related
- 1999-02-23 HU HU0101614A patent/HUP0101614A3/hu not_active Application Discontinuation
- 1999-02-23 DE DE69919515T patent/DE69919515T2/de not_active Expired - Lifetime
- 1999-02-23 ES ES99906341T patent/ES2226340T3/es not_active Expired - Lifetime
- 1999-02-23 DK DK99906341T patent/DK1056850T3/da active
- 1999-02-23 AT AT99906341T patent/ATE274058T1/de not_active IP Right Cessation
- 1999-02-23 PL PL99343079A patent/PL195990B1/pl not_active IP Right Cessation
- 1999-02-23 CN CNB998032174A patent/CN1195852C/zh not_active Expired - Fee Related
- 1999-02-23 PT PT99906341T patent/PT1056850E/pt unknown
- 1999-02-23 AU AU26312/99A patent/AU750444B2/en not_active Ceased
- 1999-02-23 CA CA002319039A patent/CA2319039A1/en not_active Abandoned
- 1999-02-23 JP JP2000532517A patent/JP2002504328A/ja active Pending
- 1999-02-23 WO PCT/GB1999/000546 patent/WO1999042577A2/en not_active Ceased
- 1999-02-23 EP EP99906341A patent/EP1056850B1/en not_active Expired - Lifetime
-
2000
- 2000-08-22 NO NO20004195A patent/NO328139B1/no not_active IP Right Cessation
-
2003
- 2003-07-11 US US10/618,570 patent/US7208291B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1590001B1 (en) | Method for in vivo regulation of cardiac muscle contractility | |
| US20060040882A1 (en) | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells | |
| US20100311161A1 (en) | Method for tissue regeneration | |
| WO2005117991A2 (en) | Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells | |
| JP2010029207A (ja) | ＨＭＧ蛋白質（ｈｉｇｈｍｏｂｉｌｉｔｙｇｒｏｕｐｐｒｏｔｅｉｎ）遺伝子の核酸配列およびそれらの使用 | |
| JPH06506470A (ja) | ＴＧＦ−β１／β２：新規なキメラトランスフォーミング増殖因子−β | |
| AU2006287481A1 (en) | Pharmaceutical compositions for delivery of ribonucleic acid to a cell | |
| EP0820310B1 (en) | Method for in vivo regulation of cardiac muscle contractility | |
| US20030216345A1 (en) | Histone deacetylase inhibitor and use thereof | |
| JP2011504375A (ja) | 細胞の中に核酸を導入する医薬組成物及びその方法 | |
| JP2002504328A5 (https=) | ||
| US7208291B2 (en) | Nucleic acids encoding biotin-binding receptors | |
| WO2007083603A1 (ja) | 治療薬 | |
| BG63548B1 (bg) | Полипептиди, съдържащи протеинови домени на gax, включени в транскрипцията и/или взаимнодействащи сдруги протеини, съответни нуклеинови киселини и тяхното използване | |
| JPH11506325A (ja) | Δｐ６２、その変異体、核酸配列及びこれらの使用 | |
| MXPA00007931A (en) | Biotin-binding receptor molecules | |
| CN120641080A (zh) | 包含十八碳神经肽(odn)及其合成衍生物的组合物以及用于调节食物摄入、肥胖、体重、恶心和呕吐的方法 | |
| WO2011079431A1 (zh) | 具有端粒酶抑制活性的融合蛋白、其制备方法和用途 | |
| JP2002509423A (ja) | 単離されたポリシアリルトランスフェラーゼ、それらをコードする核酸分子、それらの製造方法及び使用 | |
| HK1083065B (en) | Method for in vivo regulation of cardiac muscle contractility | |
| AU2010200503A1 (en) | Nucleic acid sequences in genes of the high mobility group proteins and their use |